Related Experiment Video
Updated: Aug 22, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
Pauline Lory1, Sandrine Combret1, Joelle Michot2
1Regional Pharmacovigilance Center, Dijon University Hospital, 21079 Dijon, France.
Introduction:
When the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began, there were no effective treatments assessed by clinical trials. In this context, in France, the French Public Health Council issued, from 5 March, 2020, several proposed recommendations for the therapeutic management of this new disease. This included the use of combination lopinavir/ritonavir, which is usually indicated as HIV treatment. Thanks to the reporting of adverse drug reactions (ADRs) to the French Regional Pharmacovigilance Centers, several safety signals including hepatobiliary and cardiovascular were quickly identified.
Objective:
This study aimed to compare the ADRs reported with lopinavir/ritonavir used in its usual indication prior to the pandemic with the ADRs reported with the coronavirus disease 2019 (COVID-19) indication.
Methods:
Cases of ADRs were extracted from the French Pharmacovigilance Database. ADRs were compared between the two periods: pre-COVID (1985 to 31 December 2019) and COVID (1 January 2020 to 21 July 2020).
Results:
Patients with COVID-19 were found to have a different safety profile, with significantly more damage to the liver (43% of ADRs), heart (10.6%) and kidneys (7.1%). The ADRs reported before the pandemic were mainly gastrointestinal and cutaneous.
Conclusions:
This different safety profile may be related to the effect of the virus on the organs, the patient profile (age, medical history…) and the drugs associated with lopinavir/ritonavir. Our study should serve as a reminder that the safety profile of a drug can depend on its use. Spontaneous reporting and pharmacovigilance have a critical role in alerting health professionals to "new" ADRs reported with well-known drugs.
Insights
Lopinavir/ritonavir, used for COVID-19, showed different adverse drug reactions (ADRs) compared to its HIV treatment use. COVID-19 patients experienced more liver, heart, and kidney issues, unlike earlier gastrointestinal and skin reactions.
Area of Science:
- Pharmacovigilance and drug safety research.
- Infectious diseases and public health.
- Clinical pharmacology and therapeutics.
Background:
- No established treatments for SARS-CoV-2 existed at the pandemic's start.
- Lopinavir/ritonavir, an HIV medication, was recommended for COVID-19 in France.
- Early identification of adverse drug reactions (ADRs) was crucial.
Purpose of the Study:
- To compare ADRs of lopinavir/ritonavir in COVID-19 patients versus its standard HIV indication.
- To analyze safety signals identified through pharmacovigilance.
Main Methods:
- Extracted ADR cases from the French Pharmacovigilance Database.
- Compared ADRs reported during pre-COVID (1985-2019) and COVID (2020) periods.
Main Results:
- COVID-19 patients showed significantly more liver (43%), heart (10.6%), and kidney (7.1%) damage.
- Pre-pandemic ADRs were primarily gastrointestinal and cutaneous.
- A distinct safety profile emerged for lopinavir/ritonavir in COVID-19.
Conclusions:
- The altered safety profile may stem from SARS-CoV-2 effects, patient factors, or co-medications.
- Drug safety profiles can vary based on therapeutic use.
- Pharmacovigilance is vital for detecting new ADRs with established drugs.
Related Concept Videos
Subviral Agents
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Retroviruses
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Retrovirus Life Cycles
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...

